Hematology revenue performance, protected across therapy authorization and drug payment.
Hematology revenue crosses independent groups, hospital outpatient clinics, and infusion centers. Therapy authorization must match diagnosis, regimen, dose, and service date. Clinical records must support marrow procedures, laboratory monitoring, and medical necessity. Drug units, infusion time, claim edits, payment variance, and A/R follow-up must preserve that evidence through reimbursement.
7 of top 20
U.S. health systems served
32M+
Coding charts processed annually
28M+
A/R claims managed annually
High-cost hematology revenue breaks when treatment plans, administered therapy, and claims diverge.
Hematology combines diagnostic evaluation, laboratory monitoring, procedures, and drug administration. One encounter may include several separately governed services. Missing authorization, incomplete infusion time, or incorrect drug units can delay the entire claim. Credentialed experts, RevAmp intelligence, and measurable governance connect clinical evidence with payer requirements before defects become denials, underpayments, or write-offs.
Clear therapy against payer approval before treatment
Reconcile dose, units, and infusion time before billing
Recover drug payment variance with clinical evidence
Revenue support aligned to treatment plans, infusion records, and hematologic evidence.
Hematology revenue cycle services must follow therapy from order through remittance. Risk concentrates around authorization, diagnosis specificity, administered dose, HCPCS units, infusion hierarchy, marrow documentation, laboratory evidence, and payer edits. Front-office, mid-office, and back-office work must share treatment context. Otherwise, supported services become denied, underpaid, or trapped in avoidable A/R.
Front-office
Treatment-plan and payer-authorization review - fewer regimen mismatches and therapy delays.
Mid-office
Medication record and infusion reconciliation - accurate drug units, administration codes, and charges.
Back-office
Drug remittance and denial review - fewer underpayments, write-offs, and aged high-value claims.
Protect revenue across treatment clearance, drug reconciliation, and payer adjudication.
Validate therapy approval before each administration
Authorization review aligns diagnosis, regimen, dose, and approved dates. Exceptions reach owners before treatment, preventing avoidable therapy denials and rescheduling.
Match administered dose to payer-defined drug units
Charge review compares medication records, vial use, waste, and HCPCS units. Differences receive correction before billing, preventing high-cost drug leakage.
Build infusion claims from documented sequence and time
Coding review connects route, hierarchy, and start-stop time. Supported administration services reach the claim, avoiding bundling edits and missing infusion revenue.
Separate payer reductions from legitimate drug payment
Remittance and contract variance review isolate incorrect unit reductions and pricing differences. Timely follow-up protects reimbursement before high-value balances age.
Hematology expertise, treatment-level intelligence, and drug-focused governance.
Expertise-led
Specialists who understand hematology drugs, infusion hierarchy, and marrow procedures.
- Hematology coders, authorization specialists, denial analysts, and drug-variance experts
- A named engagement lead connecting therapy operations to financial outcomes
- Calibration across drug units, infusion time, laboratory evidence, and medical necessity
Technology-powered
RevAmp turns therapy and remittance signals into earlier, prioritized action.
- Rules flag authorization gaps, unit mismatches, missing time, and high-value edits
- Dashboards connect treatment volume, coding quality, denials, variance, and aging
- Automation reduces repetitive touches while preserving expert review of therapy nuance
Operationally-governed
Treatment-level accountability supported by evidence, cadence, and corrective action.
- KPI reviews cover authorization completion, drug units, infusion evidence, and variance
- Quality audits trace defects to access, documentation, coding, or posting
- Operating reviews expose therapy queues, payer patterns, owners, and financial results
Our Vision
Open accountability: Taking responsibility without taking control.
Hematology leaders need visibility at treatment, drug, and payer levels. You retain control of protocols, clinical systems, coding standards, and escalation decisions. We bring people, RevAmp intelligence, and governance against agreed hematology measures. Modular, co-managed, and end-to-end models expose authorization exceptions, unit variance, infusion evidence, denial ownership, and financial outcomes.
Therapy authorization completion
Approval matches diagnosis, regimen, dose, and treatment date
Drug-unit accuracy
Administered dose converts correctly to payer-defined units
Infusion evidence completeness
Route, sequence, and start-stop time support administration
Regimen-to-claim reconciliation
Ordered and administered therapy matches billed lines
Drug payment variance
Incorrect reductions and pricing differences reach recovery
Why Us
Why administered therapy must reconcile before the claim reaches payer edits.
Disconnected hematology workflows lose context between authorization, administration, coding, and payment. Dose and time differences then create edits, denials, or underpayments. First-Pass Performance connects treatment plans, medication records, infusion documentation, charges, claims, and remittances. Each exception returns to the owner who can correct it before another treatment date.
Rework-Powered Cleanup Machine
Our First-Pass Performance
Treatment-plan authorization mismatch
Regimen changes surface after a high-value claim denies.
Authorized therapy reconciles with scheduled administration before treatment.
Drug-unit conversion error
Dose and billable units are corrected only after payer rejection.
Medication records and HCPCS units reconcile before claim submission.
Infusion-time evidence gap
Administration charges are reconstructed after bundling edits.
Sequence and start-stop times receive pre-bill validation.
Marrow-procedure documentation
Aspiration, biopsy, and pathology roles remain disconnected.
Procedure notes and code relationships align before professional and facility billing.
High-cost drug payment variance
Reductions remain buried in posting and aging queues.
Drug-level remittance rules route recoverable variance to accountable owners.
Revenue cycle thinking for leaders who need fewer surprises.
Explore Vee Healthtek perspectives on the forces reshaping revenue cycle performance, healthcare operations, technology adoption, and financial resilience.
Trace one therapy from authorization through drug payment.
Schedule a 30-minute working session with our hematology revenue cycle lead. Bring one pressure point: treatment authorization, drug units, infusion time, marrow coding, laboratory denials, or underpayments. We will trace where clinical evidence separates from the claim, show the financial consequence, and outline controls without displacing your team.
Continue exploring expert perspectives, industry trends, and practical strategies for improving revenue cycle performance.
Explore Points Of ViewFrequently Asked Questions
How do you reconcile administered dose with billable drug units?
What documentation supports hematology infusion administration coding?
How do you manage prior authorization across recurring treatment dates?
How do you code bone marrow aspiration and biopsy services?
Which KPIs expose hematology revenue cycle risk earliest?
How do you prevent laboratory medical-necessity denials?
How does RevAmp prioritize drug denials and underpayments?